99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

NCT05412459 · clinicaltrials.gov ↗

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Female

Interventions

DRUG: 99mTc-DARPinG3

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Collaborators

[object Object]